About Sarepta Therapeutics, Inc. - Common Stock (SRPT)
Sarepta Therapeutics is a biotechnology company focused on pioneering innovative gene therapies for the treatment of rare genetic diseases, particularly those affecting muscle disorders. The company is dedicated to developing therapies that can enable patients with conditions like Duchenne Muscular Dystrophy to achieve improved outcomes and quality of life. With a strong emphasis on research and development, Sarepta utilizes advanced techniques such as RNA-targeted therapies and gene editing to combat genetic disorders at their source. Through its work, the company aims to transform the landscape of genetic medicine and provide hope for individuals and families affected by these challenging diseases. Read More
RADNOR, PA - April 11, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta”).
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta”).
RADNOR, PA - April 8, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta”).
Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.
The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have lost 56.6% of their capital. This may have investors wondering how to approach the situation.
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
H.C. Wainwright told investors in a research note that the clinical hold on key Elevidys trials in Europe heightens the uncertainty around the future of the franchise.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 39 individuals hired by Sarepta in the first quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT)
fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price target by nearly 50% to $87. The downgrade was driven by weaker-than-anticipated feedback from physicians regarding ELEVIDYS, suggesting that market reception for the treatment had fallen short. Notably, ELEVIDYS had been a big piece of Sarepta's growth story as it contributed more than 50% of sales in the Q4'2024 quarter.
NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.
